Five-year survival of patients with non-small cell lung cancer treated with alkalization therapy.

ABSTRACT: Acidic tumor microenvironments promote malignant progression, immune evasion, and drug resistance. This single-center retrospective cohort study evaluated whether, among patients with stage IV non-small cell lung cancer (NSCLC) who participated in a pragmatic "alkalization therapy"-defined as a low potential renal acid load diet plus oral sodium bicarbonate and/or potassium/sodium citrate-urinary pH was associated with long-term survival, and whether these associations differed by EGFR/ALK mutation status. Urinary pH was used as a surrogate marker of systemic alkalization. All consecutive patients with stage IV NSCLC who first attended Karasuma Wada Clinic between January 2014, and December 2019 were included (n = 203; EGFR/ALK mutation-negative, n = 100; EGFR/ALK mutation-positive, n = 10

SUBMITTER: Kachi S 

PROVIDER: S-EPMC12859798 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature